About pegylated recombinant human factor viii
PEGylated recombinant factor VIII concentrate
Used for
- Prevention and treatment of bleeding in hemophilia A
- Bleeding control during surgery in hemophilia A
Usual adult dose
Individualized by weight, bleeding severity, and factor VIII levels; commonly 40–50 IU/kg twice weekly for prevention.
Usual dose in children
Individualized by weight and factor VIII levels; commonly 40–50 IU/kg twice weekly for prevention.
Common side effects
- Headache
- Diarrhea
- Nausea
- Allergic reactions
Important warnings
- Antibodies against factor VIII can reduce treatment effectiveness.
- Seek urgent care for severe allergic reactions, including breathing difficulty or facial swelling.
- Use only under specialist supervision; monitor factor VIII levels and inhibitor development.
- Not for von Willebrand disease or hemophilia B.
Pregnancy
Pregnancy data are limited; use only when clinically needed under specialist care.
Breastfeeding
It is unknown whether this medicine passes into breast milk; use requires clinical assessment.
Interactions
- No major drug interactions are established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.